Navigation Links
Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
Date:1/13/2009

BOSTON, Jan. 13 /PRNewswire/ -- Johnston Blakely & Company, LLC, a Boston-based life science investment bank, is pleased to announce that Michael D. Webb has joined the firm as senior advisor. In this role, Mr. Webb will participate with the firm on internal and client-related activities including merger & acquisition advisory services and private equity placements, with a particular focus on biopharmaceutical transactions. "We are delighted to have someone of Mike's caliber join the Johnston Blakely team," said Johnston Blakely founder Benjamin Conway. "His extensive senior management experience and depth of sector knowledge will be of tremendous value to both the firm and its clients."

Mr. Webb was previously President & CEO of EPIX Pharmaceuticals where he completed over $225 million in financings, including its 1997 IPO, and raised an additional $150 million through corporate partnerships. Prior to EPIX, Mr. Webb was Senior Vice President, Worldwide Marketing and Strategic Planning for Ciba Diagnostics. Most recently he has been active with Ascent Therapeutics where as founder, president & CEO he organized the company and secured its initial $20 million in venture financing. Mr. Webb holds an M.B.A. with highest honors from Northwestern University's Kellogg Graduate School of Management.

About Johnston Blakely & Company

Johnston Blakely & Company, LLC is a Boston-based investment bank offering merger & acquisition-related financial advisory and private equity placement services to companies in the life science sector. The firm incorporates the venture capital tradition of comprehensive company involvement into investment banking engagements to deliver superior results for its clients. More than investment banking...inVenture banking(TM).

Johnston Blakely is a registered broker/dealer and member of FINRA/SIPC.


'/>"/>
SOURCE Johnston Blakely & Company, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees
2. Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product
3. Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc.
4. Micromet Added to NASDAQ Biotechnology Index
5. Far From Beyond: A Glimpse into the World of Biotechnology and the Future of the Free World
6. North Carolinas Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs
7. Yongye Biotechnology Announces Record Third Quarter Results
8. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
9. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
10. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
11. InNexus Biotechnology Receives Patent Grants in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 08, 2016 , ... ... p.m. , Location: Baruch S. Blumberg Institute at the Pennsylvania Biotechnology Center of ... Blumberg Institute and The Commonwealth Medical College (TCMC) will hold an open house ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... its latest innovations on its free and validated Electronic Data Capture (EDC) system ... the Outsourcing in Clinical Trials West Coast 2016 Conference in San Mateo, California ...
(Date:2/9/2016)... SC (PRWEB) , ... February 09, 2016 , ... The ... in the organization’s history, it is offering its 2016 AAT Member Certification Qualification Course ... , The curriculum for the webinar, which will include a detailed review of hardware, ...
(Date:2/9/2016)... ... 2016 , ... PharmApprove announced today the hiring ... for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work with patients, ... drug regulatory review process. , “Adding Diane Dorman is just the latest in ...
Breaking Biology Technology:
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
Breaking Biology News(10 mins):